Mirum Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Mirum Pharmaceuticals
MIRM Stock  USD 92.29  0.10  0.11%   
Mirum Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Mirum Pharmaceuticals' valuation are provided below:
Gross Profit
377 M
Profit Margin
(0.09)
Market Capitalization
6.5 B
Enterprise Value Revenue
8.4325
Revenue
471.8 M
There are over one hundred nineteen available fundamental ratios for Mirum Pharmaceuticals, which can be analyzed over time and compared to other ratios. Self-guided Investors are advised to check Mirum Pharmaceuticals' last-minute fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 27th of February 2026, Market Cap is likely to grow to about 3.7 B. Also, Enterprise Value is likely to grow to about 3.8 B

Mirum Pharmaceuticals Total Revenue

547.38 Million

Check Mirum Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mirum Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 16.7 M, Discontinued Operations of 0.0 or Depreciation And Amortization of 28.5 M, as well as many indicators such as Price To Sales Ratio of 11.83, Dividend Yield of 0.0 or PTB Ratio of 13.23. Mirum financial statements analysis is a perfect complement when working with Mirum Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Mirum Stock
Check out the analysis of Mirum Pharmaceuticals Correlation against competitors.
To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.

Mirum Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets446.5 M842.8 M241.7 M
Slightly volatile
Other Current Liabilities206 M196.2 M42.5 M
Slightly volatile
Total Current Liabilities216.1 M205.8 M46.8 M
Slightly volatile
Other Liabilities174.9 M166.6 M59.8 M
Slightly volatile
Accounts Payable7.7 M9.6 M3.9 M
Slightly volatile
Cash311.5 M296.7 M105.8 M
Slightly volatile
Cash And Short Term Investments228.1 M383.3 M135.4 M
Slightly volatile
Common Stock Total Equity3.4 K3.6 K3.7 M
Slightly volatile
Common Stock Shares Outstanding37.7 M50.2 M29.2 M
Slightly volatile
Liabilities And Stockholders Equity446.5 M842.8 M241.7 M
Slightly volatile
Non Current Liabilities Total184.7 M322.3 M118 M
Slightly volatile
Capital Surpluse320.7 M615.3 M203.8 M
Slightly volatile
Other Current Assets19 M18.1 M4.8 M
Slightly volatile
Other Stockholder Equity583.9 M981.9 M347.1 M
Slightly volatile
Total Liabilities554.5 M528.1 M173.9 M
Slightly volatile
Total Current Assets288 M549.7 M164.6 M
Slightly volatile
Capital Stock4.3 K4.5 K3.7 M
Slightly volatile
Net Working Capital187 M306.2 M122.3 M
Slightly volatile
Common Stock4.3 K4.5 K3.7 M
Slightly volatile
Short and Long Term Debt Total333.2 M317.3 M77.7 M
Slightly volatile
Property Plant And Equipment Net11.9 M11.3 M4.7 M
Slightly volatile

Mirum Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income16.7 M15.9 M3.9 M
Slightly volatile
Depreciation And Amortization28.5 M27.2 M7.9 M
Slightly volatile
Selling General Administrative230.3 M219.3 M52.3 M
Slightly volatile
Selling And Marketing Expenses21.9 M13.2 M9.1 M
Slightly volatile
Other Operating Expenses570.6 M543.4 M142.4 M
Slightly volatile
Research Development109.3 M186.2 M54.3 M
Slightly volatile
Total Operating Expenses465.4 M443.2 M121.8 M
Slightly volatile
Reconciled Depreciation28.5 M27.2 M5.6 M
Slightly volatile

Mirum Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock13.3 M14 M51.8 M
Slightly volatile
Stock Based Compensation75 M71.4 M17.6 M
Slightly volatile
Depreciation25.5 M24.2 M5.5 M
Slightly volatile
Capital Expenditures906.3 K954 K6.5 M
Pretty Stable
Total Cash From Financing Activities38.1 M40.1 M86 M
Pretty Stable
End Period Cash Flow175 M298.2 M109.6 M
Slightly volatile
Change To Netincome19.8 M31.1 M21.7 M
Pretty Stable
Change To Liabilities10.5 M8.8 M6.6 M
Slightly volatile
Begin Period Cash Flow153.2 M222.9 M93.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio11.837.606120.2092
Slightly volatile
Days Sales Outstanding76.8486.350373.0861
Slightly volatile
Stock Based Compensation To Revenue0.130.1370.9074
Slightly volatile
Capex To Depreciation0.03740.03931.7998
Pretty Stable
EV To Sales11.527.645719.1376
Slightly volatile
Inventory Turnover2.124.02781.7187
Slightly volatile
Days Of Inventory On Hand18090.6201246
Slightly volatile
Payables Turnover10.9510.42652.1236
Slightly volatile
Sales General And Administrative To Revenue0.620.652.041
Slightly volatile
Research And Ddevelopement To Revenue0.340.35715.0271
Slightly volatile
Capex To Revenue0.00170.00180.7086
Slightly volatile
Cash Per Share4.677.63634.0854
Slightly volatile
Days Payables Outstanding33.2635.00712.5 K
Slightly volatile
Intangibles To Total Assets0.210.30960.1302
Slightly volatile
Current Ratio2.542.67113.6796
Slightly volatile
Receivables Turnover4.484.2275.2506
Slightly volatile
Debt To Equity1.061.00830.2972
Slightly volatile
Capex Per Share0.01810.0190.2437
Slightly volatile
Revenue Per Share10.910.38512.5167
Slightly volatile
Interest Debt Per Share6.346.03451.7765
Slightly volatile
Debt To Assets0.40.37650.1179
Slightly volatile
Operating Cycle286177321
Slightly volatile
Days Of Payables Outstanding33.2635.00712.5 K
Slightly volatile
Ebt Per Ebit1.770.9683.6634
Slightly volatile
Long Term Debt To Capitalization0.590.50210.5528
Very volatile
Total Debt To Capitalization0.530.50210.1469
Slightly volatile
Debt Equity Ratio1.061.00830.2972
Slightly volatile
Quick Ratio2.422.5513.6328
Slightly volatile
Net Income Per E B T0.811.09040.9928
Pretty Stable
Cash Ratio1.371.441612.2706
Slightly volatile
Days Of Inventory Outstanding18090.6201246
Slightly volatile
Days Of Sales Outstanding76.8486.350373.0861
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.930.982911.66
Slightly volatile
Fixed Asset Turnover33.6730.8918.5568
Slightly volatile
Debt Ratio0.40.37650.1179
Slightly volatile
Price Sales Ratio11.837.606120.2092
Slightly volatile
Asset Turnover0.650.61850.1798
Slightly volatile
Gross Profit Margin0.890.80770.8735
Slightly volatile

Mirum Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.7 B3.6 B1.1 B
Slightly volatile
Enterprise Value3.8 B3.6 B1 B
Slightly volatile

Mirum Fundamental Market Drivers

Forward Price Earnings39.6825
Cash And Short Term Investments383.3 M

Mirum Upcoming Events

13th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
13th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Mirum Pharmaceuticals Financial Statements

Mirum Pharmaceuticals investors utilize fundamental indicators, such as revenue or net income, to predict how Mirum Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-993.6 K-943.9 K
Total Revenue521.3 M547.4 M
Cost Of Revenue100.2 M105.3 M
Stock Based Compensation To Revenue 0.14  0.13 
Sales General And Administrative To Revenue 0.65  0.62 
Research And Ddevelopement To Revenue 0.36  0.34 
Revenue Per Share 10.39  10.90 
Ebit Per Revenue(0.04)(0.04)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Mirum Pharmaceuticals is a strong investment it is important to analyze Mirum Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Mirum Pharmaceuticals' future performance. For an informed investment choice regarding Mirum Stock, refer to the following important reports:
How To Invest In Mirum
Details
Is Mirum Stock a good investment?
Details
What is Mirum Pharmaceuticals' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Mirum Pharmaceuticals Correlation against competitors.
To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.
You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Will Biotechnology sector continue expanding? Could Mirum diversify its offerings? Factors like these will boost the valuation of Mirum Pharmaceuticals. Expected growth trajectory for Mirum significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Mirum Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(0.84)
Revenue Per Share
9.559
Quarterly Revenue Growth
0.472
Return On Assets
(0.04)
Return On Equity
(0.16)
Understanding Mirum Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Mirum's accounting equity. The concept of intrinsic value - what Mirum Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Mirum Pharmaceuticals' price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Understanding that Mirum Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Mirum Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Mirum Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY